International consensus statement on allergy and rhinology: Sinonasal tumors
Kuan E, Wang E, Adappa N, Beswick D, London N, Su S, Wang M, Abuzeid W, Alexiev B, Alt J, Antognoni P, Alonso-Basanta M, Batra P, Bhayani M, Bell D, Bernal-Sprekelsen M, Betz C, Blay J, Bleier B, Bonilla-Velez J, Callejas C, Carrau R, Casiano R, Castelnuovo P, Chandra R, Chatzinakis V, Chen S, Chiu A, Choby G, Chowdhury N, Citardi M, Cohen M, Dagan R, Dalfino G, Dallan I, Dassi C, de Almeida J, Tos A, DelGaudio J, Ebert C, El-Sayed I, Eloy J, Evans J, Fang C, Farrell N, Ferrari M, Fischbein N, Folbe A, Fokkens W, Fox M, Lund V, Gallia G, Gardner P, Geltzeiler M, Georgalas C, Getz A, Govindaraj S, Gray S, Grayson J, Gross B, Grube J, Guo R, Ha P, Halderman A, Hanna E, Harvey R, Hernandez S, Holtzman A, Hopkins C, Huang Z, Huang Z, Humphreys I, Hwang P, Iloreta A, Ishii M, Ivan M, Jafari A, Kennedy D, Khan M, Kimple A, Kingdom T, Knisely A, Kuo Y, Lal D, Lamarre E, Lan M, Le H, Lechner M, Lee N, Lee J, Lee V, Levine C, Lin J, Lin D, Lobo B, Locke T, Luong A, Magliocca K, Markovic S, Matnjani G, McKean E, Meço C, Mendenhall W, Michel L, Na'ara S, Nicolai P, Nuss D, Nyquist G, Oakley G, Omura K, Orlandi R, Otori N, Papagiannopoulos P, Patel Z, Pfister D, Phan J, Psaltis A, Rabinowitz M, Ramanathan M, Rimmer R, Rosen M, Sanusi O, Sargi Z, Schafhausen P, Schlosser R, Sedaghat A, Senior B, Shrivastava R, Sindwani R, Smith T, Smith K, Snyderman C, Solares C, Sreenath S, Stamm A, Stölzel K, Sumer B, Surda P, Tajudeen B, Thompson L, Thorp B, Tong C, Tsang R, Turner J, Turri-Zanoni M, Udager A, van Zele T, VanKoevering K, Welch K, Wise S, Witterick I, Won T, Wong S, Woodworth B, Wormald P, Yao W, Yeh C, Zhou B, Palmer J
INT FORUM ALLERGY RH. 2024;14(2):149-608.

Kopf-Hals-Tumoren
Schafhausen P
2024. Colloquium Onkologie 31. Ehninger G, F, Petrasch S (eds.). 1.. ed. München: Lukon Verlagsgesellschaft mbH München, 177-200.

Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Gotlib J, Castells M, Elberink H, Siebenhaar F, Hartmann K, Broesby-Olsen S, George T, Panse J, Alvarez-Twose I, Radia D, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward B, Schafhausen P, Vadas P, Bose P, DeAngelo D, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt N, Oh S, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall A, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti M, Bidollari I, Lin H, Sulllivan E, Mar B, Maurer M
NEJM Evidence. 2023;2023(2):.

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Isfort S, Manz K, Teichmann L, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert J, Illmer T, Schafhausen P, Al-Ali H, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke G, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf T
ANN HEMATOL. 2023;102(10):2741-2752.

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
Koschmieder S, Isfort S, Wolf D, Heidel F, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost P, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf T
ANN HEMATOL. 2023;102(2):349-358.

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma
Rieke D, Schröder S, Schafhausen P, Blanc E, Zuljan E, von der Emde B, Beule D, Keller U, Keilholz U, Klinghammer K
FRONT ONCOL. 2023;13:1107134.

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria
Tometten M, Kirschner M, Meyer R, Begemann M, Halfmeyer I, Vieri M, Kricheldorf K, Maurer A, Platzbecker U, Radsak M, Schafhausen P, Corbacioglu S, Höchsmann B, Matthias Wilk C, Hinze C, Chromik J, Heuser M, Kreuter M, Koschmieder S, Panse J, Isfort S, Kurth I, Brümmendorf T, Beier F
HEMASPHERE. 2023;7(5):e874.

Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016
Biehl L, Higgins P, Stemler J, Gilles M, Peter S, Dörfel D, Vogel W, Kern W, Gölz H, Bertz H, Rohde H, Klupp E, Schafhausen P, Salmanton-García J, Stecher M, Wille J, Liss B, Xanthopoulou K, Zweigner J, Seifert H, Vehreschild M
EUROSURVEILLANCE. 2022;27(2):.

Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia
Janjetovic S, Rolling C, Budde U, Schneppenhem S, Schafhausen P, Peters M, Bokemeyer C, Holstein K, Langer F
THROMB RES. 2022;218:35-43.

Kopf-Hals-Tumoren
Schafhausen P
2022. Colloquium Onkologie 30. Petrasch S, Ehninger G (eds.). Lukon Verlagsgesellschaft mbH München, 161-171.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
Beitzen-Heineke A, Berenbrok N, Waizenegger J, Päsler S, Gensch V, Udonta F, Vargas-Delgado M, Engelmann J, Hoffmann F, Schafhausen P, von Amsberg G, Riecken K, Beumer N, Imbusch C, Lorens J, Fischer T, Pantel K, Bokemeyer C, Ben Batalla I, Loges S
HEMASPHERE. 2021;5(9):.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord J, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R
LANCET ONCOL. 2021;22(4):463-475.

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Hecht A, Meyer J, Jann J, Sockel K, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Haferlach T, Schafhausen P, Bug G, Lübbert M, Thol F, Büsche G, Schuler E, Nowak V, Obländer J, Fey S, Müller N, Metzgeroth G, Hofmann W, Germing U, Nolte F, Reinwald M, Nowak D
ANN HEMATOL. 2021;100(6):1463-1471.

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation
Janjetovic S, Beckmann L, Holstein K, Rolling C, Thiele B, Schafhausen P, Schön G, Bokemeyer C, Langer F, Voigtlaender M
THROMB RES. 2021;198:55-61.

83/m mit Schwellung am Hals: Vorbereitung auf die Facharztprüfung: Fall 24
Zech H, Schafhausen P, Bußmann L
ONKOLOGE. 2021.

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Horne G, Stobo J, Kelly C, Mukhopadhyay A, Latif A, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf T, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark R, Milojkovic D, Helgason G, Foroni L, Nicolini F, Holyoake T, Copland M
LEUKEMIA. 2020;34(7):1775-1786.

Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg: Report of the University Cancer Center Hamburg
Weisel K, Morgner-Miehlke A, Petersen C, Fiedler W, Block A, Schafhausen P, Knobloch J, Bokemeyer C
ONCOL RES TREAT. 2020;43(6):307-313.

Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma
Zech H, Moeckelmann N, Boettcher A, Muenscher A, Binder M, Vettorazzi E, Bokemeyer C, Schafhausen P, Betz C, Busch C
FUTURE ONCOL. 2020;16(36):3035-3043.

Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients
Biehl L, Garzetti D, Farowski F, Ring D, Koeppel M, Rohde H, Schafhausen P, Stecher B, Vehreschild M
PLOS ONE. 2019;14(4):e0215428.

Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards
Biehl L, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, Panse J, Rohde H, Klupp E, Schafhausen P, Imirzalioglu C, Falgenhauer L, Salmanton-García J, Stecher M, Vehreschild J, Seifert H, Vehreschild M
CLIN MICROBIOL INFEC. 2019;25(8):1013-1020.

Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR)
Dimitriou V, Biehl L, Hamprecht A, Vogel W, Dörfel D, Peter S, Schafhausen P, Rohde H, von Lilienfeld-Toal M, Klassert T, Slickers P, Ehricht R, Slevogt H, Christ H, Hellmich M, Farowski F, Tsakmaklis A, Higgins P, Seifert H, Vehreschild M
J ANTIMICROB CHEMOTH. 2019;74(7):2065-2074.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib
Janjetovic S, Asemissen A, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P
TUMORI J. 2019;105(6):NP8-NP11.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause S, Kolb H, Hossfeld D, Nerl C, Baerlocher G, Heim D, Brümmendorf T, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler M, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne C, Lindemann H, Waller C, Spiekermann K, Berdel W, Müller L, Edinger M, Mayer J, Beelen D, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart M, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M
HAEMATOLOGICA. 2019;104(5):955-962.

Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs: Highlights des ASCO-Meetings 2019
Zech H, Laban S, Schafhausen P, Bussmann L, Betz C, Busch C
HNO. 2019;67(12):898-904.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
Gambacorti-Passerini C, Cortes J, Lipton J, Kantarjian H, Kim D, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf T, Khoury H
HAEMATOLOGICA. 2018;103(8):1298-1307.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus J, Rankin S, Clark R, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf T, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason G, Holyoake T, Loges S
CLIN CANCER RES. 2017;23(9):2289-2300.

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann W, Giagounidis A, Götze K, Lübbert M, Schlenk R, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf T, Haas R, Trümper L, Shirneshan K, Haase D
ANN HEMATOL. 2017;96(6):887-894.

Induction chemotherapy followed by radiochemotherapy for locally advanced head and neck cancer as an individual treatment approach-Feasibility, safety and retrospective survival analysis in twenty-three patients
Busch C, Girke J, Tribius S, Bussmann L, Knecht R, Schafhausen P, Lörincz B, Münscher A
CLIN OTOLARYNGOL. 2017;42(6):1392-1396.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb H, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Heim D, Brümmendorf T, Fabarius A, Haferlach C, Schlegelberger B, Müller M, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler M, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne C, Lindemann H, Waller C, Pfreundschuh M, Spiekermann K, Berdel W, Müller L, Edinger M, Mayer J, Beelen D, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart M, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J
LEUKEMIA. 2017;31(11):2398-2406.

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia:the SEPIA Study
Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause S, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely O, Vehreschild M
INT J ANTIMICROB AG. 2017;49(2):218-223.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Schlenk R, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau I, Verbeek W, Heidel F, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K
LEUKEMIA. 2017;31(4):889-895.

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Al-Ali H, Griesshammer M, le Coutre P, Waller C, Liberati A, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco J, Ghosh J, Martino B, Vannucchi A
HAEMATOLOGICA. 2016;101(9):1065-73.

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Brümmendorf T, Cortes J, Khoury H, Kantarjian H, Kim D, Schafhausen P, Conlan M, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton J
BRIT J HAEMATOL. 2016;172(1):97-110.

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Cortes J, Khoury H, Kantarjian H, Lipton J, Kim D, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf T, Gambacorti-Passerini C
AM J HEMATOL. 2016;91(12):1206-1214.

Outcome and fewer indications for adjuvant therapy for patients with oral squamous cell carcinomas under standardized tumor board conditions
Gröbe A, Rybak L, Schön G, Smeets R, Tribius S, Schafhausen P, Clauditz T, Hanken H, Heiland M
J CANCER RES CLIN. 2016;142(2):505-20.

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
Mossner M, Jann J, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk R, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann W, Germing U, Nolte F
LEUKEMIA. 2016;30(9):1956-9.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk R, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U
LEUKEMIA. 2016;30(7):1580-2.

Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature
Zielinski V, Laban S, Tribius S, Schafhausen P, Veldhoen S, Knecht R, Clauditz T, Muenscher A
ENT-EAR NOSE THROAT. 2016;95(1):23-8.

A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Borthakur G, Dombret H, Schafhausen P, Brummendorf T, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes J
HAEMATOLOGICA. 2015.

The current role of systemic chemotherapy in the primary treatment of head and neck cancer
Busch C, Tribius S, Schafhausen P, Knecht R
CANCER TREAT REV. 2015;41(3):217-21.

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller M, Hehlmann R, Hofmann W, Fabarius A, Seifarth W
PLOS ONE. 2015;10(6):e0129648.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1):an open-label, randomised phase 3 trial
Machiels J, Haddad R, Fayette J, Licitra L, Tahara M, Vermorken J, Clement P, Gauler T, Cupissol D, Grau J, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo J, Cong X, Ehrnrooth E, Cohen E
LANCET ONCOL. 2015;16(5):583-94.

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D
INT J HEMATOL. 2014;99(1):91-4.

Bosutinib: a novel second-generation tyrosine kinase inhibitor
Isfort S, Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf T
Recent Results Cancer Res. 2014;201:81-97.

Therapie von Kopf-Hals-Karzinomen
Knecht R, Busch C, Lörincz B, Schafhausen P, Tribius S, Heiland M, Jenckel F, Münscher A, Petersen C, Bokemeyer C
Hamb Ärztebl. 2014;8:12-17.

Induktionschemotherapie bei lokal fortgeschrittenen Kopf-Hals-Karzinomen – pro
Knecht R, Busch C, Schafhausen P
DEUT MED WOCHENSCHR. 2014;139(41):2080.

Imatinib
Schafhausen P
2014. Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML). Brümmendorf T, Koschmieder S (eds.). 1. ed. Bremen-London-Boston: Uni-Med, 52-59.

Kopf-Hals-Tumoren
Schafhausen P
2014. Colloquium Onkologie 18: Update Hämatologie / Onkologie 2014. Petrasch S, Ehninger G (eds.). Lukon Verlagsgesellschaft mbH München, 233-244.

Mast cell sarcoma mimicking metastatic colon carcinoma
Schwaab J, Horny H, Jonescheit J, Metzgeroth G, Schafhausen P, Gaiser T, Marx A, Kienle P, Hofmann W, Reiter A
ANN HEMATOL. 2014;93(6):1067-9.

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893)
Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K, Schafhausen P, Bockhorn M, Izbicki J, Yekebas E
BMC CANCER. 2014;14(1):411.

A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies
Vehreschild M, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal M, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild J, Cornely O, Seifert H
J ANTIMICROB CHEMOTH. 2014;69(12):3387-92.

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
Vermorken J, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler T, Keilholz U, Delord J, Schafhausen P, Erfán J, Brümmendorf T, Iglesias L, Bethe U, Hicking C, Clement P
ANN ONCOL. 2014;25(3):682-8.

Therapie der rezidivierten und fernmetastasierten Plattenepithelkarzinome des Kopf-Hals-Bereichs: Highlights des ASCO-Meetings 2014
Zeller N, Busch C, Schafhausen P, Knecht R, Möckelmann N
HNO. 2014;62(11):787-92.

Bosutinib in the management of chronic myelogenous leukemia
Amsberg G, Schafhausen P
BIOL-TARGETS THER. 2013;7:115-22.

Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study
Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf T, Bug G, Ottmann O, Giagounidis A, Stadler M, Hofmann W, Schafhausen P, Lübbert M, Schlenk R, Blau I, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D
LEUKEMIA RES. 2013;37(8):900-6.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Therapie der Rezidiv- und Fernmetastasen bei Plattenepithelkarzinomen des Kopf- und Halsbereichs: Highlights des ASCO-Meetings 2013
Hezel M, Kurzweg T, Münscher A, Schafhausen P, Knecht R
HNO. 2013;61(11):911-3.

Molecular targeting agents in the context of primary chemoradiation strategies.
Laban S, Busch C, Münscher A, Tribius S, Schafhausen P, Knecht R
HEAD NECK-J SCI SPEC. 2013;35(5):738-746.

Die wichtigsten Studienergebnisse der primären Radio-Chemo-Therapie von Kopf-Hals-Tumoren: Highlights des ASCO-Meetings 2013
Münscher A, Busch C, Schafhausen P, Tribius S, Knecht R
HNO. 2013;61(11):905-10.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

Die wichtigsten Studienergebnisse der primären Radiochemotherapie von Kopf-Hals-Tumoren: Highlights vom ASCO-Meeting 2012
Laban S, Zielinski V, Busch C, Münscher A, Schafhausen P, Tribius S, Knecht R
HNO. 2012;60(11):962-967.

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.
Marsh J, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano A, Passweg J, Killick S, Warren A, Foukaneli T, Aljurf M, Al-Zahrani H, Schafhausen P, Roth A, Franzke A, Brummendorf T, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute M, Mufti G, Socie G, Blood E, Party M
BLOOD. 2012;119(23):5391-5396.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
Neoptolemos J, Moore M, Cox T, Valle J, Palmer D, McDonald A, Carter R, Tebbutt N, Dervenis C, Smith D, Glimelius B, Charnley R, Lacaine F, Scarfe A, Middleton M, Anthoney A, Ghaneh P, Halloran C, Lerch M, Oláh A, Rawcliffe C, Verbeke C, Campbell F, Büchler M, , Schafhausen P
JAMA-J AM MED ASSOC. 2012;308(2):147-56.

Unusual course of myelodysplastic syndrome with presumed familial origin.
Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander A, Bokemeyer C, Haferlach T, Kröger N
ACTA HAEMATOL-BASEL. 2011;126(4):234-237.

Bosutinib
Keller G, Schafhausen P, Brümmendorf T
Recent Results Cancer Res. 2010;184:119-27.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf T, Atanackovic D
LEUKEMIA RES. 2010;34(12):1647-1655.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark R, Hochhaus A, Hughes T, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson R, Kantarjian H, , Schafhausen P
NEW ENGL J MED. 2010;362(24):2251-9.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

Bosutinib.
von Amsberg G, Schafhausen P, Brümmendorf T
Recent Results Cancer Res. 2010;184:119-127.

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia
Keller G, Schafhausen P, Brummendorf T
EXPERT REV HEMATOL. 2009;2(5):489-97.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E, Schafhausen P, Kröger N, Brümmendorf T, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuketang Ayuk F, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(1):6-10.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski G, Schafhausen P, Zander A, Ayuketang Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf T, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2009;50(4):551-558.

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Schafhausen P, Dierlamm J, Bokemeyer C, Brümmendorf T, Bacher U, Zander A, Schnittger S, Hochhaus A
CANCER GENET-NY. 2009;189(1):63-67.

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A, Balabanov S, von Amsberg G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf T
LEUKEMIA RES. 2008;32(12):1857-1865.

Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative.
Wellbrock J, Schultze A, Schafhausen P, Otterstetter S, Dierlamm J, Bokemeyer C, Brümmendorf T, Fiedler W, Loges S
BRIT J HAEMATOL. 2008;142(1):115-118.

Acute psychological stress alerts the adaptive immune response: stress-induced mobilization of effector T cells
Atanackovic D, Schnee B, Schuch G, Faltz C, Schulze J, Weber C, Schafhausen P, Bartels K, Bokemeyer C, Brunner-Weinzierl M, Deter H
J NEUROIMMUNOL. 2006;176(1-2):141-52.

Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial
Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, Solano C, Simonsson B, Sonnen R, Diehl V, Fischer T, Caballero D, Littlewood T, Noppeney R, Schafhausen P, Jost L, Delabarre F, Marcus R
BONE MARROW TRANSPL. 2004;34(11):955-62.

Semiquantitative reverse transcription polymerase chain reaction analysis for detection of bcr/abl rearrangement using RNA extracts from bone marrow aspirates compared with glass slide smears after 0, 2 and 4 d of storage
Schoch R, Pitako J, Schafhausen P, Jenisch S, Haferlach T, Kneba M, Suttorp M
BRIT J HAEMATOL. 2001;115(3):583-7.

Letzte Aktualisierung aus dem FIS: 31.10.2024 - 04:06 Uhr